WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a ...

Cyclin E/Cdk2 seems to play at least three roles in driving Xic1 degradation. First, cyclin E/Cdk2 forms a ternary complex with Xic1, and formation of this complex seems necessary for the ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted ...